List of Jornay Pm drug patents

Jornay Pm is owned by Ironshore Pharms.

Jornay Pm contains Methylphenidate Hydrochloride.

Jornay Pm has a total of 15 drug patents out of which 0 drug patents have expired.

Jornay Pm was authorised for market use on 08 August, 2018.

Jornay Pm is available in capsule, extended release;oral dosage forms.

Jornay Pm can be used as method of treating attention deficit hyperactivity disorder (adhd).

The generics of Jornay Pm are possible to be released after 23 March, 2032.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9028868 IRONSHORE PHARMS Methods and compositions for treatment of attention deficit disorder
Mar, 2032

(9 years from now)

US9034902 IRONSHORE PHARMS Methods for treatment of attention deficit hyperactivity disorder
Mar, 2032

(9 years from now)

US8916588 IRONSHORE PHARMS Methods for treatment of attention deficit hyperactivity disorder
Mar, 2032

(9 years from now)

US9603809 IRONSHORE PHARMS Methods of treatment of attention deficit hyperactivity disorder
Mar, 2032

(9 years from now)

US10292937 IRONSHORE PHARMS Methods of treatment of attention deficit hyperactivity disorder
Mar, 2032

(9 years from now)

US10617651 IRONSHORE PHARMS Compositions for treatment of attention deficit hyperactivity disorder
Mar, 2032

(9 years from now)

US10881618 IRONSHORE PHARMS Compositions for treatment of attention deficit hyperactivity disorder
Mar, 2032

(9 years from now)

US11241391 IRONSHORE PHARMS Compositions for treatment of attention deficit hyperactivity disorder
Mar, 2032

(9 years from now)

US11241392 IRONSHORE PHARMS Compositions for treatment of attention deficit hyperactivity disorder
Mar, 2032

(9 years from now)

US9498447 IRONSHORE PHARMS Compositions for treatment of attention deficit hyperactivity disorder
Mar, 2032

(9 years from now)

US9283214 IRONSHORE PHARMS Compositions for treatment of attention deficit hyperactivity disorder
Mar, 2032

(9 years from now)

US9023389 IRONSHORE PHARMS Compositions for treatment of attention deficit hyperactivity disorder
Mar, 2032

(9 years from now)

US8927010 IRONSHORE PHARMS Compositions for treatment of attention deficit hyperactivity disorder
Mar, 2032

(9 years from now)

US10182995 IRONSHORE PHARMS Compositions for treatment of attention deficit hyperactivity disorder
Mar, 2032

(9 years from now)

US10905652 IRONSHORE PHARMS Compositions for treatment of attention deficit hyperactivity disorder
Mar, 2032

(9 years from now)

Drugs and Companies using METHYLPHENIDATE HYDROCHLORIDE ingredient

Market Authorisation Date: 08 August, 2018

Treatment: Method of treating attention deficit hyperactivity disorder (adhd)

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in